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Introduction: Opioid consumption has increased worldwide, 
which carries the risk of opioid use disorder (OUD). However, the 
literature on OUD and opioid-related chemical coping (OrCC) 
in chronic noncancer pain (CNCP) is heterogeneous, with the 
majority of studies conducted in the United States, a country with 
high opioid consumption rates.  
Objective: To determine the frequency and predictors of 
OrCC, and the patients’ functional and psychiatric characteristics. 
Design: This was a multicenter, observational, cross-
sectional study. Set at the pain clinics of six tertiary hospitals in 
South Korea, a country with moderate opioid consumption rates. 
The patients included had CNCP and were receiving long-term 
opioid therapy (LtOT). Sociodemographic data, pain 
characteristics, and opioid information were obtained, and a 
prospective survey was conducted. Nine pain specialists evaluated 
OrCC with a questionnaire.  
Results: A total of 258 patients were included and among 
them, fifty-five (21%) patients showed OrCC. The sample had 
high pain catastrophizing (≥30 points; 66%), moderate-severe 
insomnia (≥15 points; 63%), low resilience (68 points), and high 
suicidal ideation (67%). OrCC patients had greater pain 
interference (85.18% vs. 58.28%, p = 0.017), lower satisfaction 
with the LtOT (56.4% vs 78.3%, p = 0.002), and higher worst 
numerical rating scale pain scores (8.75 ± 1.42 vs 7.95 ± 2.06, 
p = 0.001). In multivariable analysis, alcohol abuse history within 
one year (OR= 6.84, p = 0.001), prescription drugs abuse within 
one year (OR= 19.32, p = 0.016), functional pain syndrome (OR= 
12.96, p<0.001), head and neck pain (OR= 2.48, p = 0.039), 
morphine equivalent daily dose (MEDD) ≥ 200mg/d (OR= 3.48, 
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p = 0.006), and ongoing litigation (OR= 2.33, p = 0.047) were 
significant predictors of OrCC. 
Conclusion: Approximately 21% of CNCP patients receiving 
LtOT were coping chemically with opioids. The break-out of 
OrCC in CNCP in South Korea was comparable to those in 
countries with high opioid consumption, such as the United States, 
regardless of the country’s opioid consumption rate. 
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1.1. Study Background 
 
Chronic pain is a devastating disease that is often treated 
inadequately [1]. Among a plethora of treatments, opioid agonists 
are one pharmacotherapy for moderate-severe pain. Opium has 
been used for thousands of years to relieve pain and suffering, 
and after the morphine alkaloid was identified in 1806, the 
pharmacologic production of opioid drugs began [2]. In the 19th 
century, the increased availability of opioid drugs led to the 
institution of legal controls to prevent narcotic abuse. The strict 
regulatory controls on opioids and the reluctance of physicians to 
prescribe them resulted in the under-treatment of pain [3]. 
Consequently, towards the end of the 20th century, opioid therapy 
was reestablished as an invaluable and accepted treatment for 
acute, cancer, and end-of-life pain.  
The recognition that opioid therapy can relieve pain and 
improve mood and functioning in many patients with chronic pain 
led experts on pain to recommend opioids to such patients 
[2]. However, although its consumption by country (mg/capita) 
has increased in the last two decades [4-6], it may remain 
under-requirements for managing moderate-severe pain in some 
regions, including Asian countries [1,6,7]. According to the 2015 
opioid consumption data, the medical opioid consumption in the 
United States (U.S.) was 678 mg/capita while in South Korea (S. 
Korea), it was 55 mg/capita which was below average (Figure 1); 
ranking 43rd globally and 30th among thirty-five Organisation for 
Economic Cooperation and Development (OECD) countries (258 
mg/capita average in OECD countries) [6]. However, it is 
remarkable that the opioid consumption in S. Korea has increased 
5–6 times since 2005 (10 mg/capita), ranking third among Asian 
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countries preceded only by Vietnam (62 mg/capita) and Malaysia 
(60 mg/capita). 
Despite pain experts’ recommendations, many clinicians are 
reluctant to prescribe opioids to treat chronic noncancer pain 
(CNCP). Some physicians argue that opioids have a minimal effect 
on functioning and may even worsen the outcome of CNCP 
patients [2]. Additionally, there are concerns regarding the risk of 
opioid use disorder (OUD) from long-term opioid therapy (LtOT), 
secondary to the induced reward responses to the drug [8]. The 
controversy in the use of LtOT in CNCP is supported by new 
evidence of increased risk of OUD, rise in all-cause mortality, 
and poor long-term treatment results in terms of pain relief and 
quality of life [9–12]. Recently, the rising rates of opioid overdose 
deaths in countries with high opioid consumption made evident the 
risk for serious harms and the need to detect OUD early. However, 
the spectrum of OUD in CNCP is wide and varies greatly from 
opioid abuse to addiction [13].  
The abundance of status included in the OUD spectrum 
makes it difficult to determine the best way to detect promptly 
subjects at risk for addiction. Between the extremes of OUD, 
opioid-related chemical coping (OrCC) is the use of opioids to 
cope with emotional distress characterized by inappropriate 
and/or excessive opioid use [14]. OrCC should be distinguished 
from addiction, a brain disease that involves neuroplasticity and 
substantial loss of self-control [15]. All addicts are chemical 
copers, but not all chemical copers are addicts [13]. Although 
OrCC was first defined in cancer patients [16], the correlation 
with OUD in CNCP patients is high [17]. Therefore, understanding 
this intermediate status may prompt the identification of risk 





Nonetheless, the literature on OUD and OrCC is 
heterogeneous, and an overwhelming majority of the studies took 
place in the U.S. [9,19–21], a country with high opioid 
consumption rates [7] and a current opioid epidemic. In the U.S., 
drug overdose deaths (the majority involving an opioid) have 
nearly quadrupled since 1999 [4] leading to the development of 
guidelines to discourage opioid prescribing for CNCP in North 
America [22,23]. Moreover, growing evidence suggests no 
benefits of the LtOT over non-opioid therapy in CNCP patients 
[11]. However, despite the evidence and recent strict regulations 
in the U.S. and other countries with high opioid consumption, the 
‘street’ availability of illicitly manufactured opioids such as 
fentanyl keep increasing and opioid-related overdose deaths is 
not decreasing.  
In May 2018, a report calculated the number and the 
percentage of opioid-related overdose deaths in the U.S. between 
2010 and 2016 using death certificates from the National Vital 
Statistics System [24]. The researchers found that synthetic 
opioids like fentanyl caused about 46% of the 42249 opioid-
related overdose deaths in 2016. That is more than a three-fold 
increase compared with 2010, when synthetic opioids were 
involved in about 14% of opioid overdose deaths. Additionally, 
other studies suggest that CNCP remains undertreated [1,25–28] 
and stringent regulations to prevent opioid abuse and addiction 
may result in inadequate pain control [29], especially in countries 
with low opioid consumption rates [6,7]. Moreover, the lack of 
studies in countries with low opioid consumption makes it difficult 
to extrapolate results and guidelines to prevent a possible 
worldwide opioid epidemic.  Consequently, it is necessary to 
determine the frequency and characteristics of OUD in CNCP 
patients in countries with low-moderate opioid consumption rates, 
to ascertain if OUD is indeed correlated with the country’s overall 
consumption rates of opioids (mg/capita). 
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1.2. Purpose of Research 
 
We performed a national, multicenter, observational study 
to address OrCC, the intermediate status of OUD, in LtOT for 
CNCP in S. Korea, a country with moderate opioid consumption 
rates since 2010 [7]. Addressing OrCC instead of OUD in a 
country with moderate rates of opioid consumption such as S. 
Korea may help us to assess a bigger quantity of patients at risk 
for severe harms in an early stage. The objectives of this study 
were to estimate the frequency of OrCC in a sample of CNCP 
patients, to evaluate the patient’s functional and psychiatric 
characteristics, and to determine the risk factors independently 

























Figure 1. South Korea total opioid consumption  
 
This figure depicts a comparison of the opioid consumption 
(morphine equivalence mg/capita) in the Americas region versus 
S. Korea from 1990–2015. Although S. Korea’s opioid 
consumption has increased yearly since 2005, it remains low in 
comparison to the Americas region. Sources: International 
Narcotics Control Board/ World Health Organization population 
data. By: Pain & Policy Studies Group, University of 








2. Materials and Methods 
 
 
This national, observational, cross-sectional study was 
conducted in eight tertiary university-based hospitals in S. Korea 
between April 2017 and January 2018. The study was conducted 
in accordance with the Declaration of Helsinki, and the 
Institutional Review Boards (IRB) in each hospital approved the 
protocol. The protocol of the study was registered and openly 
shared in ClinicalTrials.gov (NCT03161795) to stress in the 
transparency of the research conduction.  
Eleven pain specialists, one neuropsychiatrist, and one 
oncologist took part in the study. Written informed consent was 
obtained from each participant prior enrollment. All methods and 




2.1. Study Participants 
 
Inclusion criteria: (1) age ≥18 years; (2) diagnosis of 
chronic pain defined by the International Association for the Study 
of Pain (IASP) as persistent or recurrent pain lasting longer than 
3 months or past the time of normal tissue healing [31]; (3) 
patients with LtOT defined as the current and regular use of one 
or more opioid prescriptions for ≥ 3 months; and (4) patients 
who completed the questionnaires administered in the study. 
Exclusion criteria: (1) patients with a cancer diagnosis 
and/or receiving ongoing cancer treatment, palliative care, or 
end-of-life care; (2) patients who received opioid therapy for < 
3 months or intermittently; (3) patients with serious systemic 
diseases (hepatic or renal failure, acute cardiac ischemic disease, 
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etc.), or acute psychiatric disorders that required inpatient 
management (schizophrenia, anxiety, depression, etc.), which 
compromised their safety or the completion of the study; or (4) 




2.2. Evaluation of Opioid-Related Chemical Coping 
 
Eleven anesthesiologists, one neuropsychiatrist, and one 
oncologist in the initial expert meeting discussed the evaluation of 
OrCC. The presence of OrCC was determined through a 
questionnaire that contained seven behaviors related to OrCC. 
The questionnaire was based in a previous study of OrCC [14] 
and the Diagnostic and Statistical Manual of Mental Disorders fifth 
edition (DSM-5) diagnostic criteria of OUD [32] (Table 1 and 2). 
 The questionnaire was reviewed through two additional 
educational meetings that were held prior to the patient’s 
enrollment to reduce bias between physicians. A pain specialist at 
each participating hospital evaluated the presence of OrCC using 
the study’s questionnaire. Two or more affirmative answers to the 
questionnaire were considered positive for OrCC. 
There is a previously developed scale to measure OrCC, 
the chemical coping inventory (CCI) [13]. The CCI asks patients 
with opioid-treated pain to indicate the extent to which they 
agree with 15 statements describing nonprescribed use of 
medications to cope with emotional stress. Although the CCI was 
pre-validated in one study [13] and showed high internal 
consistency in another study [17], there are no further validation 
studies. In our study, pain physicians evaluated OrCC thus the 




2.3. Outcome Measurements 
 
Patients’ sociodemographic data were obtained from the 
electronic medical record (EMR) including educational level 
(<high school graduate or ≥high school graduate) and religion 
(yes = Christianity, Islam, Buddhism, Hinduism, Taoism, etc.; no 
= Atheism), pain characteristics including pain intensity using an 
11-point numerical rating scale (NRS) [33], co-morbid 
psychopathologies (depression, anxiety, bipolar disorder, etc.), 
substance abuse history within one year, and secondary morbid 
gain (if the patient’s pain allows him/her to miss work, avoid 
military duty, obtain financial compensation, obtain drugs, etc.). 
We also collected opioid information, which included the duration 
of administration in months, opioid name and type, administration 
route (oral, transdermal, intrathecal, intravenous), morphine 
equivalent daily dose (MEDD, mg/day) [34], initial prescribers of 
the opioid, number of opioid-seeking visits per year to the opioid 
provider or the emergency room (ER), and co-prescription of 
benzodiazepines or other medications (anticonvulsants, 
antidepressants, topical agents, etc.).  The information that was 
unavailable in the EMR was asked directly to the patient when 
appropriate using an individualized survey (Appendix 1). The 
tools and questionnaires administered in this study were divided 
into patient’s and physician’s booklets. The physician’s booklet 
included the questionnaire to assess the patient’s OrCC (Table 1 
and 2) and the patient’s booklet contained predictive tools for 
OUD and questionnaires to address functionality (Appendix 2 and 
3). 
The risks of LtOT were assessed through a survey in the 
outpatient setting of each pain clinic. After obtaining written, 
informed consent, the patients received a patient’s booklet and 
responded to the following questionnaires and forms: (1) Cut 
down, Annoyed, Guilty, Eye-opener Adapted to Include Drugs 
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(CAGE-AID) [35]; (2) Brief Pain Inventory-Short Form (BPI-
SF) [36]; (3) Pain Catastrophizing Scale (PCS) [37]; (4) Hospital 
Anxiety and Depression Scale (HADS) [38]; (5) Insomnia 
Severity Index (ISI) [39]; (6) Korean Instrumental Activities of 
Daily Living Scale (K-IADL) [40]; (7) Korean Connor-Davidson 
Resilience Scale (K-CD-RISC) [41]; and (8) Patient Global 
Impression of Change Scale (PGIC) [42].  
Among the four questions in the CAGE-AID, one or more 
affirmative answers was considered “positive” for OUD [43]. 
BPI-SF measured pain intensity (Items 3–6) and pain 
interference (Item 9) [44], which had seven components scored 
from 0 (no interference) to 10 (interferes completely). PCS had 
13 items rated from 0 (not at all) to 4 (all the time); a total score 
≥30 was considered “catastrophizing” [37]. HADS scores for 
anxiety and depression ranged from 0 to 21, with ≥11 points 
considered “abnormal” [45]. The ISI total score ranged 0–28; 
scores ranging from 15–21 and 22–28 indicated moderate and 
severe insomnia, respectively [46]. K-IADL evaluated daily 
activities with 11 questions rated from 0 (independently 
performed/normal) to 3 (impossible to perform) [47]. K-CD-
RISC had 25 items, rated from 0–4, with higher scores reflecting 
greater resilience [48]. PGIC was rated from 1 (very much 
improved) to 7 (very much worse) [49]. Patients’ overall 
satisfaction with their LtOT ranged from 1 (extremely satisfied) 
to 5 (extremely unsatisfied). A question to evaluate the presence 
of suicidal ideation in CNCP was also included (yes = previous 
suicidal attempts, thoughts of ending one’s life, planned to commit 
suicide, wish to be dead; no = never attempted or thought about 
committing suicide). Additionally, adverse and undesirable effects 
of opioids were collected. 
On the survey day, after answering the patient’s booklet, 
each patient attended a routine visit with a pain specialist. Once 
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the patient exited the room, the specialist answered the 
questionnaire to assess the patient’s OrCC included in the 
physician’s booklet. The same process was reproduced with all 
the subjects included in the study and was supervise by a 
designated research nurse. 
 
  
2.4. Sample Size Calculation and Statistical Analysis 
 
The precision/absolute error and the significance level 
were set at 5% and 95%, respectively (Type 1 error of 5%, α = 
0.05). According to a published study by Kwon et al. [19], the 
prevalence of chemical coping was approximately 18%; therefore, 
the sample size was calculated to be 235 participants. Considering 







The precision/absolute error and the significance level 
were set at 5% and 95%, Depending on the data distribution, 
independent t-tests or Wilcoxon rank sum tests were performed 
to compare two independent groups. A paired t-test was used to 
compare two means from the same group. Categorical data were 
analyzed using Pearson’s χ2 test, Fischer’s exact test or Chi-
square test. The normality distribution for continuous variables 
was assessed with the Kolmogorov–Smirnov test. The 
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independent t-test was used to compare normal distribution and 
the Mann–Whitney U test was used for non-normal distribution. 
Univariable analysis was performed to explore variables 
associated with OrCC, using the presence of OrCC as a dependent 
variable and clinical variables that included sociodemographic data, 
pain characteristics, opioid information, and scores of CAGE-AID, 
K-IADL, PCS, ISI, K-CD-RISC, HADS, BPI-SF, and PGIC as 
independent variables. Clinical variables with a p-value < 0.1 in 
univariable analysis were considered for multivariable analysis. 
The multivariable regression analysis was conducted by manual 
forward stepwise selection, and variables with a p-value < 0.05 
were retained. All parametric data were presented as mean ± 
standard deviation (SD) and nonparametric data as percentage 
(%) or odds ratio (OR) with a 95% confidence interval (95% CI). 
All p-values are two-tailed, and p-values < 0.05 were 
considered statistically significant. Statistical analyses were 



















Table 1. Opioid-related chemical coping questionnaire 
 
1. Please read carefully the definition of opioid-related chemical 
coping: 
“Opioid-related chemical coping is the use of opioids to cope with 
emotional distress characterized by inappropriate and/or excessive 
opioid use” [14]. 
2. The following are aberrant behaviors related to chemical coping 
with opioids. Please mark all the behaviors which you believe the 
patient presents: 
Behavior Check 
 Use of opioids other than for the prescribed purpose 
to treat non-nociceptive symptoms (cope with 
emotional or spiritual distress, anxiety, depression, 
insomnia, fatigue, anger, etc.). 
 
 
 Excessive use (more than prescribed according to 
appropriate titration) of PRN (pro re nata) doses 
despite no benefits added to pain relief or quality of 
life.  
 
 The patient has obtained or stolen prescription opioids 
from another person (family member, friend, etc.).  
 
 The patient asks the physician to prescribe a specific 
opioid or certain amount of the opioid.  
 
 Impulsive or excessive use of the prescribed opioids 
despite several and persistent secondary effects 
(drowsiness, nausea, vomiting, constipation, etc.) 
 
 The patient has insisted aggressively to receive 
higher doses of an opioid for storage purposes, 
prevention, fear, etc.  
 
 The patient keeps losing the prescription of opioids 
and often seeks to visit the opioid provider to get new 
prescriptions and feel reassured. 
 
 
Two or more affirmative statements were considered positive for OrCC. 
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Table 2. 마약성 진통제 관련 화학적 설문지 
 
 
1. 마약성 진통제 관련 화학적 대처의 정의를 주의 깊게 읽으십시오: 
“마약성 진통제 관련 화학적 대처란 정서적 고통에 대처하기 
위해 마약성 진통제를 부적절하거나 과다하게 사용하는 것을 의
미합니다.” [14]. 
2. 다음은 마약성 진통제에 대한 화학적 대처와 관련된 비정상적인 
행동들입니다. 환자가 보인다고 생각되는 행동에 모두 표시해 
주십시오. 
행동 표지 
 환자가 처방 받은 마약성 진통제를 통증과 관계없는 증상
을 위하여 복용하고 있습니다. (정서적 또는 심리적 고통, 
불안, 우울감, 불면, 피로, 분노 등에 대처하기 위하여). 
 
 
 환자가 통증의 감소나 삶의 질의 향상에 도움이 되지 않
음에도 불구하고 과도하게 PRN으로 처방된 마약성 진통
제를 사용하고 있습니다. (적절한 용량 결정에 의해 처방 
받은 양보다 더 많이). 
 
 다른 사람 (가족, 친구 등)에게 처방된 마약성 진통제를 
얻거나 훔쳐서 복용합니다.  
 
 환자가 의사에게 특정 약물을 지정하거나 원하는 용량을 
처방할 것을 요구합니다. 
 
 몇 가지 지속적인 부작용들 (졸음, 메스꺼움, 구토, 변비 
등)에도 불구하고 처방된 마약성 진통제를 충동적으로 또
는 과다하게 사용합니다. 
 
 환자가 의사에게 약물 보관, 발생할지 모르는 증상의 예
방, 두려움의 해소 등을 목적으로 높은 용량의 마약성 진
통제를 처방할 것으로 공격적으로 주장합니다. 
 
 환자가 처방전을 자꾸 잃어버리며 마약성 진통제를 다시 
처방받기 위해 여러 병원을 찾아 다니는 양상을 보입니다. 
 
 






A total of 258 CNCP patients receiving LtOT, in six of eight 
hospitals, were included in the study (Figure 2). Patients from 
two hospitals were excluded due to delayed IRB approval. Based 
on the pre-defined consensus and the questionnaire for chemical 
coping, 55 patients (21%) were classified as OrCC. 
The patients were divided into two groups according to a 
positive assessment for OrCC (the coping group (n = 55) and 
control group (n = 203)). Table 3 demonstrates the patients’ 
sociodemographic data and clinical characteristics. The sample 
was homogenous in terms of ethnicity (all patients were Asian 
and only one patient was non-Korean), sex, BMI, marital status, 
employment, and religion. The average pain duration was 74.55 
months (95% CI: 66.68 – 82.43), the shortest was 4 months and 
the longest 440 months (mode = 16 months). When compared to 
the control group, patients in the coping group were younger 
(48.58 ± 12.25 years vs. 53.79 ± 13.54 years; p = 0.038) and 
with an education level greater or equal to high school level 
(90.9% vs. 73.9%; p = 0.007).  
Although the reduction of NRS pain score from the initial to 
final visit was significant within each group (p < 0.001 in controls 
and p = 0.048 in copers), it was less than one point in both 
groups. Pain in the head and neck, functional pain syndrome, and 
mixed pain were more common in copers (27.3% vs. 13.3%, p = 
0.013; 18.2% vs. 2.5%, p < 0.001; and 18.2% vs. 8.4%, p = 0.035, 
respectively). Alcohol and/or medication abuse, and prescription 
drug use with alcohol within one year, were remarkably frequent 
in copers when compared to non-copers (20.0% vs. 3.9%, p < 
0.001; 9.1% vs. 0.5%, p < 0.001; and 22.6% vs. 8.5%, p = 0.02, 
respectively). More copers had co-morbid depression (50.9% vs. 
27.6%, p = 0.001) and reported ongoing litigation (27.8% vs. 
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13.9%, p = 0.010). Additionally, an overwhelming 66.7% of the 
sample (n = 172) had suicidal ideation related to their chronic 
pain. 
The opioid information is shown in Table 4. The duration of 
opioid administration and number of patients with co-prescription 
(including benzodiazepines) was not significantly different 
between groups. Although the opioid types (long-acting vs. 
short-acting) were similar in both groups, rapid-onset fentanyl 
and intravenous injections were more frequent in the coping group 
(14.5% vs. 3.4%, p = 0.005 and 10.9% vs. 3.0%, p = 0.023, 
respectively). The average MEDD was significantly higher in the 
copers than the non-copers (169 ± 186 mg/day vs. 119 ± 227 
mg/day, p = 0.006). Additionally, patients with MEDD ≥100 and 
≥200 mg/day were more frequent in the coping group (32.7% vs. 
21.2%, p = 0.033 and 25.5% vs. 9.9%, p = 0.002, respectively). 
The number of annual visits to an opioid prescriber and the 
number of patients who visited the ER seeking for opioids was 
significantly higher in the copers than non-copers (36.35 ± 
53.93 visits vs. 19.07 ± 18.86 visits, p = 0.023 and 27.3% vs. 
4.4%, p < 0.001, respectively). The first opioid prescriber was 
not significantly different between groups; and in 81% of the 
sample, the first opioid prescriber was a pain specialist. 
Table 5 shows the questionnaires and predictive tools used 
in the study. Although the proportion of patients with a positive 
CAGE-AID was higher in the copers (80.0% vs. 66.5%), it did not 
reach statistical significance (p = 0.054). The PCS was over 30 in 
both groups, indicating a “catastrophic” appraisal of pain. The 
“worst” NRS item of the BPI-SF was higher, and the general 
activity, mood, and sleep interference were worse in the copers 
than the non-copers (p = 0.001, p = 0.043, p = 0.013, and p = 
0.021, respectively). The K-IADL score and percentages were 
higher in the coping group (p = 0.031 and p = 0.017, 
respectively). Both groups reported high anxiety and depression 
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in HADS, moderate clinical insomnia in the ISI, and low resilience 
in the K-CD-RISC. 
About 74% of the subjects were extremely or somewhat 
satisfied with their LtOT, and the percent of patients unsatisfied 
was significantly more prevalent among copers vs. non-copers (n 
= 24, 44% vs. n = 44, 22%; p = 0.002). A total of 14 patients 
were extremely unsatisfied and among them 12 replied that the 
opioids were not effective (“it doesn’t work”, “there is no pain 
relief”) and 2 patients that they were afraid of addiction. The 
PGIC was similar in both groups, the patients were moderately 
better with a slight but noticeable change. Two patients answered 
that they were much worse after receiving opioids, one in the 
control and the other in the coping group. There were no 
differences in the adverse or undesirable effects between groups, 
and 62% of the patients reported at least one event. The most 
frequent adverse effect was constipation (n = 105, 40.7%) 
followed by somnolence (n = 62, 24.0%) and nausea (n = 50, 
19.4%). 
Figure 3 shows the independent predictors of OrCC 
identified in multivariable analysis. The risk of OrCC increased in 
patients with: (1) prescription drugs abuse, Odds ratio (OR) = 
19.32, 95% CI = 1.75–213.81, p = 0.016; (2) alcohol abuse, OR = 
6.84, 95% CI = 2.26–20.69, p = 0.001; (3) functional pain 
syndrome, OR = 12.96, 95% CI = 3.47–48.45, p < 0.001; (4) head 
and neck pain, OR = 2.48, 95% CI = 1.05–5.88, p = 0.039; (5) 
MEDD ≥ 200 mg/day, OR = 3.48, 95% CI = 1.43–8.48, p = 
0.006; and (6) ongoing litigation, OR = 2.33, 95% CI = 1.01–5.39, 
p = 0.047. Additionally, age < 55 years, OR = 2.17, 95% CI = 
0.99–4.76, p = 0.052 and BPI-SF mood interference ≥ 8, OR = 






























Figure 2. Flow diagram of participants 
 

























Screened subjects (1205) 
PP Analysis Group per Hospital (258) 
Exclusion of analysis (0) 
- Drop out or loss data (0) 
PP Analysis Group (258) 
 
Not comply with inclusion (947) 
- Chronic pain < 3 months (154) 
- Opioid use < 3 months (289) 
- Intermittent use of opioids (390) 
- Cancer pain (66) 
- Incomplete data (48) 
Coping Group (55) Control Group (203) 
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(n = 258) 
Control 
(n = 203) 
Coping * 
(n = 55) 
p Value 













Age, mean±SD, years 52.89±3.36 53.79±13.54 48.58±12.25 0.038 
Ethnicity, n (%), Asian 258 (100) 203 (78.7) 55 (21.3) - 
BMI, mean±SD, kg/m2 24.81±4.03 24.89±3.87 24.51±4.58 0.544 

















Education level, n (%) 
< high school 












Employment status, n(%) 
Unemployed and 
























Chronicity of pain, mean 
±SD, months 
74.55±64.25 73.23±66.09 79.44±57.23  0.526 
NRS, mean±SD, points 
Initial 
Current 
 Absolute change 
P-value of absolute 
change 


































































Location of pain, n (%) 
Head & Neck 
Chest or Abdomen 
Back 
Extremities 
















































< 0.001‡   
0.035 
Substance abuse history 
within 1 year, n (%) 
Yes 
  Tobacco 
  Alcohol 
  Medication 
  Illicit drugs 


































drugs with alcohol 
within 1 year, n (%) 
29 (11.2) 17 (8.5) 12 (22.6) 0.002 
Concurrent 
psychopathology, n (%) 
Yes 
  Depression 
  Anxiety 



























  Bipolar disorder 









Secondary morbid gain, 
n (%) 
Miss work or studies 


























This table depicts the data and statistical analysis of the patients’ 
demographic and clinical characteristics  
 
______________________________________ 
*  A physician with the OrCC questionnaire evaluated the 
presence of OrCC. Two or more affirmative answers were 
positive for OrCC. 
† Values from Mann-Whitney U test 
‡ Values from Fisher's exact test 
§ Whole body or genitalia 
 
BMI: body mass index; NRS: 11-point pain numerical rating scale; 
























(n = 258) 
Control 
(n = 203) 
Coping * 
(n = 55) 
p Value 
Duration of opioids, 
mean±SD, months 













Opioid types, n (%) 
Long-acting 


















































≥100 mg/d, n (%) 

















Number of visits per 
year to the opioid 
provider, mean±SD 
22.77±30.71 19.07±18.86 36.35±53.93 0.023 
ER visits seeking 
opioids, n (%) 
24 (9.3) 9 (4.4) 15 (27.3) < 0.001 

















































120 (46.5) 95 (46.8) 25 (45.5) 0.859 

























Physical therapy, n 
(%) 
32 (12.4) 28 (3.9) 4 (7.4) 0.203 
 
 
This table depicts the data and statistical analysis of the patients’ 
opioid consumption and other treatments information.  
 
______________________________________ 
*  A physician with the OrCC questionnaire evaluated the 
presence of OrCC. Two or more affirmative answers were 
positive for OrCC. 
† Values from Mann-Whitney U test 
‡ Gynecology, internal medicine, neurology, neuropsychiatry, 
orthopedics, otorhinolaryngology. 
 





















(n = 258) 
Control 
(n = 203) 
Coping * 
(n = 55) 
p Value 


































NRS on average 
NRS right now 
Pain relief (%) 




















































































PGIC, n (%), better 108 (41.9) 89 (43.8) 19 (34.5) 0.215 
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Satisfaction scale, †  
Satisfied, n (%)  















≥11 points, n (%) 
Depression, mean±
SD, points 
































severe), n (%) 
























67.95±22.06 68.77±22.24 64.91±21.30 0.250 
 
 
This table depicts the data and statistical analysis of the patients’ 
responses to the questionnaires and predictive tools evaluated in 
this study.  
 
______________________________________ 
*  A physician with the OrCC questionnaire evaluated the 
presence of OrCC. Two or more affirmative answers were 
positive for OrCC. 
† Satisfied = extremely satisfied and somewhat satisfied, 
unsatisfied = somewhat unsatisfied and extremely unsatisfied. 
 
BPI-SF: brief pain inventory – short form; CAGE-AID: cut 
down, annoyed, guilty, eye-opener – adapted to include drugs; 
HADS: hospital anxiety and depression scale; ISI: insomnia 
severity index; K-IADL: Korean–instrumental activities of daily 
living; K-CD-RISC: Korean-Connor-Davidson resilience scale; 
PCS: pain catastrophizing scale; PGIC: patient global impression of 















Figure 3. Forest plot of multivariable analysis showing the factors independently associated with o
pioid-related chemical coping 
This figure shows the distribution of risk probabilities per factor associated with OrCC.  
______________________________________ 
BPI: brief pain inventory; CI: coefficient interval; MEDD: morphine equivalent daily dose; OR: Odds ratio.  
Variable OR (95% CI) 
Prescription drugs abuse within 1 year 19.32 (1.75 - 213.81) 
Alcohol abuse within 1 year 6.84 (2.26 – 20.69) 
Functional pain syndrome 12.96 (3.47 – 48.45) 
Location of pain in head & neck 2.48 (1.05 – 5.88) 
MEDD ≥ 200 mg/d 3.48 (1.43 – 8.48) 
Age < 55 years 2.17 (0.99 – 4.76) 
Ongoing litigation 2.33 (1.01 – 5.39) 
BPI Mood interference ≥ 8 1.84 (0.90 – 3.77) 
Overall 6.43 (1.05 – 11.80) 
Favors Coping Disfavors Coping 
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Chapter 4. Discussion 
 
 
This study evaluated the rate of OrCC, patient 
characteristics, and risk factors of OrCC in a group of CNCP 
patients receiving LtOT. The frequency of OrCC was 21%, which 
indicates that about one out of every five CNCP patients used 
opioids to cope with emotional distress. There is a scarcity of 
research regarding the frequency of OrCC, except for one study 
[19], which reported a rate of 18% in palliative care patients in 
the U.S. Therefore, to the best of our knowledge, this is the first 
study to evaluate the rate of OrCC in CNCP. Our results 
demonstrate that the frequency of CNCP patients coping 
chemically with opioids is as high as that found in cancer patients 
[19]. Furthermore, it is comparable to the rate of misuse (21–
29%) determined in a recent systematic review that included 35 
studies from the U.S. and three studies from the European Union 
(EU) [21]. Our results show that OrCC in CNCP is comparably 
high to OUD rates, even in countries with low-moderate opioid 
consumption. Therefore, the risk of OUD seems to be independent 
of the country’s opioid consumption rate (mg/capita), and the 
countries with low-moderate opioid consumption may have an 
underestimated opioid problematic.  
Regarding patients’ demographics, previous studies 
reported that young age and male sex are common risk factors for 
OUD and dependency [50,51]. In this study, younger patients 
were more likely to be classified in the coping group and 
conversely patients 70 years or older were frequently found in 
the control group. Another survey of 25,864 patients in the U.S. 
also found that old age was associated with lower rates of OUD 
[52]. Although the copers were younger, patient sex was not 
statistically significant, which correlates with another OrCC study 
[19]. OrCC patients had high level of education compared to the 
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non-copers, which contradicts previous studies in substance 
abuse and dependence [53,54]. The discrepancy in our finding 
may be explained as an interaction effect between age and level of 
education (correlation coefficient = −0.178, p = 0.005). In our 
study, younger patients had higher level of education and 
conversely older patients had lower than high school education 
level. A recent report found that 66% of Koreans, between the 
age of 25 and 34 years, attained tertiary education, while only 8% 
of Korean women aged 55–64 years did it [55]. Therefore, 
younger patients with an increased liability to OrCC had higher 
education levels, which may explain our results.  
Although there were no differences in the job status 
between coppers and controls, most of the CNCP patients were 
informal workers (n = 83, 32.3%) or unemployed (n = 122, 
47.3%).  Other studies found that chronic pain is negatively 
associated with an individual’s employment, thus job loss is a 
frequent consequence of the patient’s catastrophizing of pain, 
health care dissatisfaction, and pain disability [56,57]. Another 
interesting finding was that most of the CNCP patients were single 
(n = 185, 72%). Marriage has been associated with longer life and 
better health in both men and women. One study found a strong 
association of the marital status with emotional suffering but not 
with negative illness beliefs and concluded that widowed patients 
have better psychological resilience to chronic pain [58]. 
However, the population of married people is decreasing yearly, 
and younger people are inclined to cohabitate or remain single 
thus studies correlating marital status with chronic pain may 
prove difficult to conduct. In S. Korea, according to census 
statistics released on March 2018, the number of marriages 
recorded in 2017 fell 6.1% from the previous year achieving a 
rate of 5.5 marriages per 1000 people, the lowest level since 
1970 [59]. The trend among young Koreans is to choose a single 
lifestyle, which has contributed to a low birthrate and converted 
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the country in the world’s fastest-aging developed economy. 
In terms of the pain characteristics, the overall patients in 
this study complained of moderate to severe pain with an NRS 
pain score over seven points at their initial visits. Despite LtOT, 
however, their pain improvement on the last measurement was 
trivial with only 8.6% reduction in the pain severity and only 1 
point in the NRS scale. In addition, the prevalence of 
posttraumatic stress disorder (PTSD) in the study’s sample was 
relatively high (n = 52, 20.2%) without significant differences 
between the groups. PTSD patients have more risk factors for 
pain, including higher rates of psychiatric and substance use 
disorders [60], which may explain the high frequency of the 
disorder found in this study. Another interesting result in this 
study was that head and neck pain increased 2.5 times (p = 
0.039), and functional pain disorders increased 13 times the risk 
of OrCC (p < 0.001) in our multivariable analysis. Functional pain 
syndromes typically concur with anxiety, depression, and chronic 
fatigue syndrome [61], conditions for which opioids are usually 
ineffective [62]. Therefore, the treatment of chronic functional 
pain should be centered in non-opioid pharmacotherapy with 
active use of physiotherapeutic and psychological methods to 
improve coping with pain [63]. Moreover, patients receiving LtOT 
without improvement in the pain control should be evaluated to 
assess the real contribution of opioids and to reduce drug toxicity. 
Major depression and alcohol or drug abuse are known risk 
factors for OUD and OrCC [18,63,64] which is concordant with 
our result. Markou et al. [65] asserted that depression has 
neurobiological effects similar to those in alcohol or opiate 
withdrawal syndromes. Hence, patients with underlying 
depression may self-medicate with opioids to correct their 
dysfunctional systems. Our sample had high HADS scores without 
statistically significant differences between groups, which may be 
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explain by the scale’s low specificity (~50%) and sex/age-
related biases [66], and due to the high prevalence of anxiety and 
depression in chronic pain patients with LtOT. In addition, alcohol 
and prescription drug abuse also increased seven (p = 0.001) and 
19 times (p = 0.016) the risk of OrCC in our results. The 
concomitant use of alcohol and opioids is associated with OUD, 
OrCC and worse outcomes [67], which is consistent with our 
result (p = 0.002). Therefore, CNCP patients with alcohol and/or 
prescription drug abuse history require special attention due to an 
increased risk of OrCC, opioid toxicity, and poor outcomes. 
Similar to previous studies in OUD [68,69], patients with 
OrCC received significantly higher dosages of opioids (p = 0.006) 
in this study. Interestingly, doses of 100–200 mg/day were not 
different among the groups (p = 0.878). However, dosages ≥200 
mg/day almost quadrupled the risk of OrCC (p = 0.002). Another 
study from the U.S. also found increased OUD rates with dosages 
≥200 mg/day, without differences at 100 or 120 mg/day [70]. 
Therefore, dosages ≥200 mg/day should be concerning in CNCP 
due to a high correlation with OrCC and OUD. In terms of opioid 
types, rapid-onset opioids (ROOs) were prescribed more 
frequently in the coping group. ROOs are used for the 
management of breakthrough pain (BTP) in opioid-tolerant 
patients with cancer or noncancer pain [70–73]. Although the 
evidence linking ROOs to OUD is limited [74,75], our results 
support that ROOs may potentiate OUD. A cautious use of ROOs in 
CNCP patients is recommended and further studies that evaluate 
its association with OUD are needed. Additionally, frequent visits 
to the provider and/or the ER seeking for opioids was correlated 
with OrCC (p = 0.001 and p < 0.001, respectively). Therefore, 
although pseudo-addiction should be initially discarded as a cause 
of opioid seeking [76], frequent hospital and ER visitors must be 
evaluated for OUD. 
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The BPI-SF showed increased pain interference, and the 
K-IADL indicated an increased compromise of daily activities in 
the copers. Our results suggest that decreased functionality and 
high pain interference constitute risk factors of OrCC [77,78]. 
Ongoing litigation doubled the risk of OrCC. Although previous 
studies have not linked litigation with OUD, this process causes 
negative emotions that accentuate the underlying pain with anger, 
frustration, and helplessness [79], which may induce OrCC. 
Furthermore, two-thirds of the sample had catastrophic thinking 
and moderate-severe insomnia. Pain catastrophizing is associated 
with pain severity, altered CNS pain processing, and exaggerated 
pain-related interference [80]. Our sample had low resilience 
(68/100 points), compared to the U.S. general population average 
(80/100 points) [40]. These findings highlight the role of 
psychological therapy in improving pain-coping skills and 
functionality in CNCP patients [81,82]. 
Contrary to previous studies on chemical coping [19,76], in 
this study, the CAGE-AID questionnaire was not significantly 
positive in the OrCC group when compared to the controls (p = 
0.054). Interestingly, CAGE-AID positives were found in 66.5% 
of the controls, whereas 20% negatives were copers. This result 
infers that CAGE-AID is a predictive, but not a diagnostic tool for 
OUD with a low specificity [19,83]. Moreover, the questionnaire 
focuses on addiction and may not detect risky use in non-
dependent individuals [35], as in our study population. Another 
distinctive result is that pain specialists were the predominant 
opioid prescribers. S. Korea’s strict regulations on opioids and the 
difficulties of storage and administration limit their use by primary 
specialists [84]. Conversely, in the U.S., the primary care 
specialty groups accounted for nearly half (44.5%) of all 
dispensed opioid prescriptions during 2007–2012 [85]. 
Additionally, insufficient training in the management of CNCP and 
excessive focus on the treatment with opioids may lead to its 
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over-prescription and the under-detection of OUD [86,87]. 
Accordingly, the mean amount of opioids prescribed per person in 
2015 in the U.S. was 640 mg/day (0.1–5543 mg/day) [4], almost 
five times the mean in our study 129 mg/day (4.5–2700 mg/day). 
Another remarkable finding in this study is the absence of 
illicit drug abuse reports. This result may be secondary to deep-
rooted cultural and social stigmatization of illicit drugs in Asia 
[88]. In Asia drugs are ill seen by society and its possession, 
distribution, and use are severely punished by law. Historically, S. 
Korea has been viewed as a drug-free country when compared to 
the U.S., Japan, and other countries [89]. Traditional drugs, 
including heroin and cocaine, are not commonly used in S. Korea, 
as reflected by drug seizure and arrest data [90]. However, drug 
availability has increased since 2006 due to globalization and 
economic expansion [90]. Nonetheless, it is still difficult and 
expensive to obtain illicit substances in S. Korea, thus the ‘street’ 
use of drugs among young adults and students is limited. In the 
U.S., the poor results in the reduction of overall overdose deaths 
with the guidelines in opioid prescription has led to a change of 
strategies. In 2018, the U.S. government has centered in law 
enforcement to reduce drug supply, prevention and education by 
ad campaigns, and job-seeking assistance for individuals fighting 
addiction [91]. The efforts to combat opioid addiction are directed 
now to achieve public awareness and to sweep the legislation to 
include promoting research that find new drugs for pain 
management and expand the treatment for substance use 
disorders for Medical patients. The results of the new U.S. 
government strategies will prove its efficacy in the years to come. 
In the meantime, the strict laws on illicit drug-use in S. Korea 
seem to be effective in controlling overdose deaths and 




There are several limitations to be addressed. First, this 
study took place only in tertiary hospitals. This may be associated 
with biases for generalization since the patients in this study may 
have more challenging pain syndromes than those in primary 
institutions. Second, the questionnaire used to evaluate OrCC was 
a result of an expert meeting; however, it is not a validated tool. 
In addition, although there were three consensus and educational 
meetings prior to patient enrollment, there might be detection 
biases between pain specialists. Nonetheless, OrCC is a clinical 
phenomenon accurately assessed by experienced providers [16], 
thus, a high predictability of true positives may be expected. 
Moreover, in this study, OrCC was evaluated immediately after 
each visit to avoid inappropriate scoring or recall biases. Third, 
our sample size was relatively large (n = 258); however, a broad 
CI of some OrCC risk factors in our multivariable analysis, such as 
prescription drug abuse (OR = 19.32 (95% CI = 1.75–213.81)) or 
functional pain syndrome (OR = 12.96 (95% CI = 3.47–48.45)), 
would be a limitation. Another drawback is that the study’s data 
depended on statements from patients. Although there was 
assurance of confidentiality, patients’ responses may not always 
be reliable. Finally, urine drug test and opiate immunoassay, which 
are considered “gold standards” to assess OUD [9], were not 
conducted. Barriers to cost-effectiveness and accessibility 










Chapter 5. Conclusion 
 
Approximately 21% of the CNCP patients receiving LtOT 
are chemically coping with opioids, carrying high intensity of pain, 
and experiencing severe interference in daily activities. The high 
rates of OrCC found in this study suggest that the break-out of 
OUD in CNCP of S. Korea is comparable to those in countries with 
high opioid consumption, such as the U.S., regardless of the 
country’s opioid consumption rates. Therefore, we should be 
vigilant about OUD in CNCP patients with LtOT. The independent 
risk factors of OrCC are prescription drugs and alcohol abuse, 
functional pain syndrome, pain in the head and neck, MEDD ≥ 
200 mg/day, and ongoing litigation. Although further validation 
studies are warranted, the assessment of OrCC may prompt the 
identification of patients at high risk for severe OUD. Finally, 
although our result has suggested that, there is no benefit of LtOT 
in CNCP; more research is needed to establish the rationale of 
evidence-based opioid prescription that should be limited to 
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다음 중 질문에 답해 주십시오 
 
1.1. 마약성 진통제를 처음 처방 받은 과(의사)는 어디 입니까? 
0 – 가정의학과의사 
1 – 일반내과의사 
2 – 외과의사 
3 – 응급의학과의사 
4 – 통증의학과의사 




1.2. 마약성 진통제 복용 후 부작용을 경험한 적이 있습니까?  
(네 / 아니오) 
 





1.3. 현재 다른 병원에서 받고 있는 통증치료가 있습니까?  
(네 / 아니오) 
 





1.4. 현재 정신건강의학과 진료를 보고 있습니까? (네 / 아니오) 
 





1.5. 자살에 대해 생각해 본 적이 있습니까? 
0 – 한번도 없었다 
1 – 한번이상 있다 




1.6. 실패한 자살 행동이 있습니까?      
 




1.7. 군 복무를 하였습니까?   
 
0 – 아니오      1 – 네       2 - 해당 없음  
 
 
1.8. 현재 진행중인 법적 소송이 있습니까?    
 






Appendix 2. Questionnaires and scales in Korean 
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2.7. Hospital Anxiety and Depression Scale, HADS (병원   
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Appendix 3. Other questions to patients 
 
 
3.1. Patient’s Global Impression of Change (PGIC) 
 
귀하의 마약성진통제 효과에 대한 질문입니다. 다음 중 하나에 
표시해 주십시오.  
 
마약성 진통제 복용을 통해 나의 통증은:  
1 – 아주 많이 나아진다 
2 – 많이 나아진다 
3 – 아주 조금 나아진다 
4 – 변화가 없다 
5 – 아주 조금 나빠진다 
6 – 많이 나빠진다 




3.2. Other sociodemographic characteristics 
 
다음 중 질문에 답해 주십시오 
1) 나는 (미혼, 기혼) 이다 
2) 나는 (한국인, 외국인) 이다 
3) 나는 (중졸, 고졸, 대졸, 대졸이상) 이다 
4) 나는 종교가 (있다, 없다) 
5) 나는 흡연가 (이다, 아니다) 






 Abstract in Korean 
 
마약성 진통제를 장기간 복용하는 만성 
비암성 통증 환자에서 마약성 진통제와 
연관된 화학적 대처  
– 다기관, 관찰, 단면 조사 연구 - 
 
 





서론: 전세계적으로 증가하고 있는 마약성 진통제의 소비는 마약성 진
통제 사용장애의 위험을 야기하고 있다. 그러나 만성 비암성 통증 환
자에서 마약성 진통제 사용장애와 마약성 진통제와 연관된 화학적 대
처에 관한 대부분의 연구는 미국과 같이 마약성 진통제 소비율이 높은 
나라에서 주로 이루어지고 있어 일반화하여 적용하기 어려운 실정이다. 
방법: 마약성 진통제와 연관된 화학적 대처의 빈도와 예측인자를 알아
보고 환자들의 기능적, 정신적 특성을 살펴본다. 이 연구는 다기관 관
찰 단면 조사 연구이다. 
대한민국에서 중등도의 마약성 진통제 소비율을 보이는 여섯 개 3차 
병원의 통증 클리닉의 환자들을 대상으로 연구가 이루어졌다. 
장기간 마약성 진통제를 복용하고 있는 만성 비암성 통증 환자. 
사회인구학적 정보, 통증의 특성, 마약성 진통제에 대한 자료를 얻고 
전향적 설문조사를 시행한다. 9명의 통증 전문가가 설문지를 통해 마
약성 진통제와 연관된 화학적 대처에 대해 평가하게 된다. 
 
 ６５ 
결과: 총 258명의 환자들 중 55명 (21%)의 환자가 마약성 진통제와 
연관된 화학적 대처 양상을 보였다. 이 환자들의 조사에서는 높은 정
도의 극단적 통증 인지 (≥30 points; 66%), 중등도 이상의 불면증 
(≥15 points; 63%), 낮은 회복력 (68 points), 높은 자살 사고 
(67%)가 특징적으로 관찰되었다. 마약성 진통제와 연관된 화학적 대
처를 보이는 환자들은 높은 정도의 통증 간섭을 보이고 (85.18% vs. 
58.28%, p = 0.017), 장기간의 마약성 진통제 사용에 대한 만족도가 
낮으며 (56.4% vs 78.3%, p = 0.002), 가장 극심한 통증 정도를 표
현한 숫자통증등급에서 더 높은 수치를 보였다 (8.75 ± 1.42 vs 
7.95 ± 2.06, p = 0.001). 다변량 분석 결과 1년 이내 알코올 남용
이 있었던 경우 (OR= 6.84, p = 0.001), 1년 이내 처방 받은 약의 남
용이 있었던 경우 (OR= 12.96, p<0.001), 두경부의 통증 (OR= 2.48, 
p = 0.039), 일일 모르핀 환산 용량이 200mg 이상인 경우 (OR= 
3.48, p = 0.006), 법률적 문제가 지속되는 경우 (OR= 2.33, p = 
0.047) 등이 마약성 진통제와 연관된 화학적 대처를 유의하게 예측할 
수 있는 인자로 나타났다. 
결론: 장기간 마약성 진통제를 처방 받는 만성 비암성 통증 환자의 약 
21%에서 마약성 진통제와 연관된 화학적 대처를 보이는 것으로 나타
났다. 이 연구에서 나타난 마약성 진통제와 연관된 화학적 대처의 높
은 발생률은 만성 비암성 통증 환자의 마약성 진통제 사용장애의 발생
이 해당 국가의 마약성 진통제 소비율과는 독립적인 관계임을 보여주
고 있다. 
 
주요어: 만성 비암성 통증; 마약성 진통제; 마약성 진통제 사용장애; 
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